Iron deficiency anemia or IDA is among one of the top ten most important public health issues, according to the World Health Organization. With approximately one-third of the current global population facing the problem of iron deficiency, more and more people are likely to suffer from a lack of iron in their diet in the near future due to changes in eating habits and rising life expectancy.
Currently, iron supplements used in the context of IDA account for the majority share of the iron-based medicines but this is likely to change with the growing utility of intravenous iron (IV) drugs. Earlier, the IV iron market was mainly achieved in the hemodialysis (HD) setting, but IV iron is likely to be used more in many other therapeutic areas which are highly under-penetrated.
One of the major attractiveness of IV iron especially in regions outside the United States is its pricing and growing number of CKD population. Generally the pricing of IV irons outside the U.S. is lower and the iron market in countries like China is underdeveloped, but growing rapidly, with tremendous potential.
Venofer from Galenica Limited has emerged as the undisputed leader in the IV iron drugs market overtaking the market share of Watson’s InFed and Ferrlecit. Still the whole IV iron market holds immense business opportunities mainly because of increase in the number of haemodialysis patients and limitation in various iron replacement therapies and scope for innovation.
The report titled “Global Intravenous (IV) Iron Drugs Market: Potential Opportunities” analyzes the IV iron market in the context of opportunities it holds for iron drug manufacturers. The report presents statistics on the growing population of patients who are suffering from critical conditions that calls for the need of iron drugs. Further, it analyzes the factors that could drive the growth of IV drugs market in the future. It also profiles the two major manufacturers of iron drugs - Galenica and Watson Pharma. Further, the future growth of the IV iron drugs market has been analyzed in the report.
(0 items)
